Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499233 | 1.00 | ADORA2A (0.64) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL2480941 | 0.92 | ADORA2A (0.62) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL31439427 | 0.91 | ADORA2A (0.61) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL28645388 | 0.91 | ADORA2A (0.56) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL29047902 | 0.90 | ADORA2A (0.60) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL29047905 | 0.90 | ADORA2A (0.60) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL2761074 | 0.89 | MEN1 (0.66) | ADORA2AADORA2B | |
| SCHEMBL3500482 | 0.89 | MEN1 (0.66) | ADORA2AADORA2B | |
| SCHEMBL6429185 | 0.89 | ADORA3 (0.66) | — | |
| SCHEMBL155837 | 0.89 | SLC29A1 (0.75) | ADORA2AADORA2BALDH1A1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986697-B1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-7834171-B2 | Modified polynucleotides for reducing off-target effects in RNA interference | DHARMACON, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100184209-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-1986697-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080242851-A1 | MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET EFFECTS IN RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| WO-2007095387-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070173476-A1 | MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE | DHARMACON INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20060223777-A1 | Highly functional short hairpin RNA | DHARMACON, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20050223427-A1 | Modified polynucleotides for reducing off-target effects in RNA interference | DHARMACON, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173476-A1 | MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE | PHAX, NSUN2, RNMT | ADORA2A 1375/4885ADORA2B 1284/4885TP53 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.